Chapman Financial Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$137K Sell
2,200
-845
-28% -$53.4K 0.09% 143
2026
Q2
$175K Hold
3,045
– – 0.12% 133
2026
Q1
$185K Sell
3,045
-347
-10% -$20.2K 0.13% 135
2025
Q4
$183K Sell
3,392
-242
-7% -$11.6K 0.12% 133
2025
Q3
$164K Sell
3,634
-3,303
-48% -$154K 0.11% 138
2025
Q2
$321K Buy
+6,937
New +$341K 0.27% 82
2024
Q4
$496K Buy
+8,767
New +$490K 0.4% 72

Other funds holding BMY

Chapman Financial Group's BMY Position: Q3 2026 in Review

Chapman Financial Group reduced its Bristol-Myers Squibb (BMY) stake by 28% in Q3 2026, selling an estimated $53.4K and leaving 2,200 shares worth $137K. The position accounts for 0.09% of the portfolio, ranked #143.

Chapman Financial Group first reported a position in BMY in Q4 2024 and has held it in 7 quarters since. The position peaked at $496K in Q4 2024. 2,569 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Chapman Financial Group held 2,200 shares of Bristol-Myers Squibb worth $137K as of Q3 2026.
  • Chapman Financial Group sold 845 Bristol-Myers Squibb shares in Q3 2026, an estimated $53.4K.
  • Bristol-Myers Squibb made up 0.09% of Chapman Financial Group's portfolio in Q3 2026, its #143 holding.
  • Chapman Financial Group first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 7 quarters since.
  • Chapman Financial Group's Bristol-Myers Squibb position peaked at $496K in Q4 2024.
  • 2,569 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Chapman Financial Group's 13F filing for Q3 2026, filed 26 Oct 2026.